Dimerix (DXB) Short Interest
Dimerix (ASX:DXB) had 0.00% of shares reported as short positions as of 24 Aug 2026, representing 26,405 shares. Dimerix operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Dimerix
Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred pharmaceutical products for global markets. Their focus is on identifying and developing drugs for areas with unmet needs, particularly in inflammatory diseases affecting the kidney and lungs.
Short position
Dimerix (ASX:DXB) has 0.00% of its shares on issue reported as short positions as of 24 Aug 2026, or about 26,405 shares. Over the past 30 days that figure has fallen 0.05 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.48% in March 2025. DXB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4DXB intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Dimerix
Latest DXB news
All newsAbout
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss DXB
Start a research thread or post the first pulse update